The profile is currenly unclaimed by the seller. All information is provided by CB Insights.

cytegen.com

Stage

Unattributed | Alive

Total Raised

$2.45M

Last Raised

$1.1M | 7 mos ago

About CyteGen

CyteGen is a medical company that aims to extend people's lives by correcting age-related sickness and pain in the body. The business has discovered chemicals that promote the elimination of defective mitochondria while promoting the creation of new, healthy mitochondria, allowing doctors to use genomes, proteomics, and biochemical data to optimize cellular metabolism.

CyteGen Headquarter Location

4230 N. Oakland Avenue #154

Milwaukee, Wisconsin, 53211,

United States

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

CyteGen Patents

CyteGen has filed 1 patent.

patents chart

Application Date

Grant Date

Title

Related Topics

Status

7/22/2016

Transcription factors, Cell biology, Ageing, Cell signaling, Clusters of differentiation

Application

Application Date

7/22/2016

Grant Date

Title

Related Topics

Transcription factors, Cell biology, Ageing, Cell signaling, Clusters of differentiation

Status

Application

Latest CyteGen News

🔒 Wauwatosa-based CyteGen raises another $1.1 million for anti-aging research

Jan 13, 2022

By Share The accelerator building on the UWM Innovation Campus in Wauwatosa. Wauwatosa-based CyteGen has raised another $1.1 million to fund their research into extending human life and reversing age-related decline. A Jan. 13 SEC filing shows the company raised the $1.1 million in equity through three… Want to Read More? Paid BizTimes subscribers get unlimited access to all Insider content and much more. Learn more in our Insider FAQ . Wauwatosa-based CyteGen has raised another $1.1 million to fund their research into extending human life and reversing age-related decline. A Jan. 13 SEC filing shows the company raised the $1.1 million in equity through three investors. This is their second funding round. The company also raised $1 million back in April of 2018. CyteGen Corp. was co-founded in 2015 by Nuray George Ugras and is based in the UWM Innovation accelerator at 1225 Discovery Parkway in Wauwatosa. The company is focused on mitochondrial dysfunction’s link to aging and neurodegenerative disorders such as Parkinson’s and Alzheimer’s.CyteGen’s team includes experts and researchers from the Medical College of Wisconsin, the University of Wisconsin-Madison, Johns Hopkins University, the University of California-San Francisco Parnassus Campus, biopharma company GlaxoSmithKline, MIT and more.CyteGen was also awarded $252,092 in September of 2020 though a Small Business Technology Transfer (STTR) grant. The company was listed as still being in Phase 1, which means they are still in the concept development phase.According to award information found on the STTR website, CyteGen was seeking funding to test the hypothesis that “endurance exercise stimulates the release of circulating factors that improve mitochondrial fitness.” CyteGen’s goal is to identify these endogenous factors and engineer them to treat diseases in which mitochondrial dysfunction. Sign Up Now Sign up for BizTimes Daily Alerts Stay up-to-date on the people, companies and issues that impact business in Milwaukee and Southeast Wisconsin

  • Where is CyteGen's headquarters?

    CyteGen's headquarters is located at 4230 N. Oakland Avenue, Milwaukee.

  • What is CyteGen's latest funding round?

    CyteGen's latest funding round is Unattributed.

  • How much did CyteGen raise?

    CyteGen raised a total of $2.45M.

  • Who are the investors of CyteGen?

    Investors of CyteGen include Breakout Labs.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.